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Previously we developed tubulin inhibitor, Hsp27 inhibitor and
dual Hsp27 and tubulin inhibitors that exhibited potent anti-cancer
activity [22]. In addition, the combination of pure tubulin inhibitor
with Hsp27 inhibitor showed a synergistic effect to inhibit cancer
cell proliferation [22], suggesting that the compounds with dual
molecular targets have advantages over agents with single molec-
ular target. It is desirable to further optimize the dual targeting
compounds to generate new analogs with better potency to inhibit
both Hsp27 and tubulin, which will lead to more potent anti-cancer
agents. In the current study, systematic ligand based optimization
resulted in compounds that significantly inhibited breast cancer
cell proliferation. Unexpectedly, the Hsp27 inhibitory activity of the
compounds was diminished during the lead optimization. The new
derivatives became pure tubulin inhibitors. The results revealed
several key structural elements critical for Hsp27 inhibition, which
provides important structural characteristics for future optimiza-
tion to improve Hsp27 inhibition.
2. Results and discussions
2.1. Lead optimization and summarization of the structureeactivity
relationship (SAR)
Previously, we have shown that structural modification of the
lead compound 1 (Fig. 1) by substitution of 2,5-dimethylbenzyl
moiety with 2,5-dimethoxybenzyl group dramatically increased
the inhibition of cell proliferative activity. Several new derivatives
inhibited the proliferation of various cancer cell lines with IC50
values at subnanomolar level [22]. Additionally, replacing methyl
sulfonamide group in these compounds with trifluoromethyl sul-
fonamide group significantly impaired their anti-cancer activity,
suggesting that the trifluoromethyl sulfonamide group is not well
tolerated. Since no other alternatives to methyl sulfonamide group
were investigated in the previous study, we wonder if a bulkier or
more hydrophobic group, such as propyl, phenyl, or benzyl at this
position, could be tolerated. Therefore, in this study we kept the B
moiety as 2,5-dimethoxybenzyl group, and systematically changed
the C moiety to several different sulfonamide groups including
ethyl-, propyl-, phenyl-, and benzyl-sulfonamide. The acetamide
group, which is smaller than the methyl sulfonamide group and
shows different electronic distribution, was also evaluated. Previ-
ous studies revealed that the N-methyl group at the D position is
important for the anti-proliferative activity of methyl sulfonamides.
Removal of N-methyl group significantly decreased their cell
growth inhibitory potency [22]. In this study, we further confirmed
this structureeactivity relationship on this moiety with this series
of compounds. Some analogs were designed as free eNH moiety
and some were designed as eMethyl NH moiety. For all the new
derivatives, moiety A was remained as 4-methoxyphenyl, 3,4-
dimethoxyphenyl, 4-bromophenyl, and 4-iodophenyl group. The
previous evaluation of 39 different aryl groups at the A position
revealed that these four substituted aryl groups were superior to
other ones [22].
All these new compounds were synthesized according to the
previous method (Scheme 1) [22]. They were examined for potency
and selectivity on the growth inhibition of four different breast
cancer cells lines including SKBR-3, MCF-7, MDA-MB-231, and
MDA-MB-468. SKBR-3 cell is human epidermal growth factor re-
ceptor 2 (HER2) positive and estrogen receptor (ER) negative, while
MCF-7 cell is HER2 negative and ER positive. Both MDA-MB-231
and MDA-MB-468 cells are HER2 and ER negative. The results are
summarized in Table 1. The IC50s of cell growth inhibition of the
compounds ranges from 0.001 mM to 2.44 mM for SKBR-3 cells,
0.001 mM to 186.0 mM for MCF-7 cells, 0.1 mM to 48.1 mM for MDA-
MB-231 cells, and 0.008 mM to 1.010 mM for MDA-MB-468 cells.
Most compounds exhibited more potent growth inhibition to
SKBR-3 andMDA-MB-468 cells thanMCF-7 andMDA-MB-231 cells.
For SKBR-3 cells, SAR analysis indicated that the sulfonamide group
at the C moiety of these compounds is critical for the biological
activity. The previously synthesized compounds N-methyl-
methanesulfonamide 2e5 showed potent anti-proliferative activity
for SKBR-3 cells with IC50 values about 0.001e0.004 mM [22].
However N-methylethanesulfonamides (6, 14, 16), N-methyl-pro-
pylsulfoylamides (7, 11, 15, 17), N-methyl-benzylsulfoylamide (8),
and N-methyl-phenylsulfonamides (9, 13) showed decreased ac-
tivity compared to the corresponding N-methyl-
methanesulfonamide (2e5). Only N-methylethanesulfonamide 10
and N-methylbenzylsulfonamide 12 maintained the potent SKBR-
3 cell growth inhibition activity with IC50s of 0.001 mM and
0.003 mM respectively. The general order of potency of various N-
methyl alkyl/arylsulfonamides for inhibition of SKBR-3 cell growth
is methanesulfonamides > ethanesulfonamides > ¼ propyl-
sulfonamides > benzylsulfoylamides > phenylsulfonamides. The
anti-proliferative activity of the compounds against SKBR-3 cells
seems to be inversely proportional to the size of alkyl/aryl sulfon-
amide at the C moiety. Previous study showed that removal of the
N-methyl group in N-methylmethanesulfonamides significantly
impairs their biological activity [22]. Similar phenomenon was
observed for most N-methyl alkyl/arylsulfonamides evaluated in
the current study. Removal of N-methyl group in N-methyl-
ethanesulfonamides (10, 14, 16), N-methyl-propylsulfonamides (7,
11, 15, 17), N-methyl-benzylsulfonamide (8, 12), and N-methyl-
phenylsulfonamides (9, 13), generated the corresponding ethane-
sulfonamides (22, 26, 28), propylsulfonamides (19, 23, 27, 29),
benzylsulfonamide (20, 24), and phenylsulfonamides (21, 25) with
2e43 fold loss in potency. The results confirmed that the free eNH
moiety of these compounds decrease the anti-cancer activity. Free-
NH can act as a hydrogen bond donor or acceptor, whereas methyl-
NR can only act as hydrogen bond acceptor. The hydrogen bond
formation on this moiety may be critical for the biological activity
Fig. 1. Ligand based optimization of compound 1.
of the corresponding compounds. A sole hydrogen bond acceptor
on this moiety benefits the anti-cancer activity based on the cell
proliferation assay results. Ethanesulfonamide 18 is exceptionally
as potent as N-methylethanesulfonamide 6. Four acetamide de-
rivatives 30e33 exhibited anti-proliferative activity with IC50s in
the range of 0.110 mMand 2.44 mM. All of them aremuch less potent
than corresponding N-methyl-alkyl/arylsulfonamides (6e17) and
alkyl/arylsulfonamides (18e23, 26e29) with the exception of
acetamide 33. This compound is as potent as the corresponding
benzylsulfonamide 24 and 3-fold more potent than phenyl-
sulfonamide 25. The results suggest that sulfonamide group is
preferred over acetamide group for the anti-cancer activity.
A similar trend was observed in the SAR studies for MDA-MB-
468, MDA-MB-231, and MCF-7 cells. For the inhibition of MDA-
MB-468 cell growth, the most potent compounds were N-methyl-
benzylsulfonamide 8 and N-methyl-propylsulfonamide 11 with
same IC50s of 0.008 mM. Two potent compounds for growth inhi-
bition of MCF-7 cells were N-methylethanesulfonamide 10 and
propylsulfonamide 23 with IC50 of 0.015 mM and 0.050 mM. Unex-
pectedly, N-methylethanesulfonamide 6 inhibited MCF-7 cell
growth with an IC50 of 0.001 mM, which is superior to all other
compounds. The result suggested that the compoundmay interfere
with some unknown cell growth pathways to block cell prolifera-
tion besides the identified tubulin and Hsp27 pathways. Most of the
other compounds showed activity at submicromolar levels for
MCF-7 cells, and are even much less potent for inhibition of MDA-
MB-231 cell growth.
2.2. Inhibition of tubulin polymerization
Previous studies revealed that 2,5-dimethoxybenzyl group can
enhance the tubulin polymerization inhibitory potency of the
compounds, thereby substantially improve their anti-proliferative
activity. In the current study, this critical group was remained
and various alkyl/arylsulfonamides were synthesized and evalu-
ated by substitution of other moieties. Among these new analogs,
N-methylethanesulfonamide 10 and N-methylbenzylsulfonamide
12 displayed potent cytotoxicity against SKBR-3 cells with IC50s of
0.001 mMand 0.003 mM, respectively. This potency is comparable to
that of the corresponding N-methylmethanesulfonamide 5. How-
ever, the two compounds have different sulfonamide moieties.
Therefore, it is necessary to elucidate whether the compounds act
through similar anti-cancer mechanisms compared to the lead
compounds. First, their tubulin inhibitory activity was determined
with tubulin polymerization assay. Both compounds 10 and 12
showed dose-dependent inhibition of tubulin polymerization
(Fig. 2). In 15 min, compound 10 inhibited tubulin polymerization
by 9% at 0.1 mM and 59% at 1 mM. Compound 12 displayed a similar
tubulin polymerization inhibitory activity by 5% at 0.1 mM and 56%
at 1 mM. These inhibitory activities of compounds 10 and 12 are
Scheme 1. Reagents and conditions: (a) 2,5-dimethoxybenzyl chloride, K2CO3, DMF; (b) R2SO2Cl, NaH, DMF (c) Acetyl chloride, K2CO3, 1,4-dioxane; (d) MeI, NaH, DMF; (e) FeCl3, Zn,
DMF/H2O; (f) R1COCl, K2CO3, 1,4-dioxane.
Table 1
SAR of alternate A and B moiety methanesulfonamide.
H
N OO
R1 N
6-29
H3CO
OCH3
R3
SO O
R2
H
N OO
R
NH
30-33
H3CO
OCH3
O
Entry R1(R) R2 R3 IC50 (mM)
SKBR-3 MCF-7 MDA-MB-231 MDA-MB-468
6
OCH3
CH2CH3 CH3 0.021  0.004 0.0008  0.0006 2.03  1.12 0.014  0.005
7
OCH3
n-C3H7 CH3 0.026  0.02 0.074  0.042 0.42  0.29 0.057  0.021
8
OCH3
PhCH2 CH3 0.06  0.02 0.23  0.09 14.2  8.81 0.008  0.004
9
OCH3
Ph CH3 0.06  0.03 1.25  0.59 0.87  0.51 0.08  0.02
10
I
CH2CH3 CH3 0.001  0.0002 0.016  0.01 0.125  0.07 0.012  0.005
11
I
n-C3H7 CH3 0.007  0.003 0.14  0.06 17.9  12.2 0.008  0.003
12
I
PhCH2 CH3 0.003  0.001 0.12  0.06 2.25  1.51 0.012  0.005
13
I
Ph CH3 0.05  0.02 2.88  1.72 0.8  0.44 0.05  0.01
14
OCH3
OCH3
CH2CH3 CH3 0.056  0.021 0.097  0.06 0.1  0.06 0.088  0.059
15
OCH3
OCH3
n-C3H7 CH3 0.05  0.02 1.27  0.69 0.69  0.41 0.07  0.02
16
Br
CH2CH3 CH3 0.012  0.005 0.16  0.1 0.5  0.31 0.056  0.022
17
Br
n-C3H7 CH3 0.019  0.01 0.06  0.03 21.7  14.5 0.072  0.032
18
OCH3
CH2CH3 H 0.019  0.008 11.9  6.64 0.16  0.09 0.048  0.017
19
OCH3
n-C3H7 H 0.071  0.021 0.28  0.17 4.6  2.4 0.025  0.007
comparable to that of N-methylmethanesulfonamide 5 from the
previous study [22] (see Fig. 3).
2.3. Tubulin docking studies
In the previous study, lead compound 1 was found to be a
colchicine site binder on tubulin [23]. We anticipate the new de-
rivatives 10 and 12 should also target the colchicine-binding site in
tubulin, due to their structural similarity to compound 1. To further
elucidate the interaction between tubulin and compounds 10 and
12, we performed a docking study of these two compounds into the
colchicine-binding site in tubulin. The results are shown in Fig. 4.
Compound 10 may form three major interactions with tubulin.
First, 2-methoxyl group in 2,5-dimethoxybenzyl moietymay form a
hydrogen bond with the side chain of Ser 178. There may be some
polar contact between the sulfonamide group and side chains such
Table 1 (continued )
Entry R1(R) R2 R3 IC50 (mM)
SKBR-3 MCF-7 MDA-MB-231 MDA-MB-468
20
OCH3
PhCH2 H 0.19  0.09 1.29  0.7 1.83  1.01 0.09  0.04
21
OCH3
Ph H 0.31  0.11 16.7  7.44 12.4  5.9 0.72  0.23
22
I
CH2CH3 H 0.026  0.005 0.44  0.12 19.8  13.1 0.073  0.029
23
I
n-C3H7 H 0.047  0.023 0.05  0.03 1.84  0.73 0.019  0.007
24
I
PhCH2 H 0.12  0.04 1.69  0.91 1.78  0.86 0.11  0.03
25
I
Ph H 0.34  0.17 39.6  21.7 5.74  3.07 0.18  0.06
26
OCH3
OCH3
CH2CH3 H 0.108  0.048 2.48  1.55 0.53  0.29 0.061  0.019
27
OCH3
OCH3
n-C3H7 H 0.096  0.037 0.29  0.16 5.66  2.02 0.45  0.14
28
Br
CH2CH3 H 0.085  0.031 2.51  1.5 2.31  1.29 0.042  0.014
29
Br
n-C3H7 H 0.074  0.025 0.36  0.21 20.6  11.4 0.24  0.09
30
OCH3
0.38  0.13 1.17  0.49 19.0  6.25 0.25  0.08
31
OCH3
OCH3
1.24  0.32 1.81  0.7 31.7  8.65 0.99  0.25
32
Br
2.44  1.53 186.0  99.3 48.1  23.6 1.01  0.44
33
I
0.11  0.02 0.31  0.17 3.65  1.87 0.29  0.04
as Glu 183 and Asn 101. Additionally, the carbonyl group of benzoyl
amide moiety may form a hydrogen bond with the main chain of
Ala 250. The docking investigation showed that compound 10 has
strong binding affinity to the colchicine-binding site of tubulin.
Compared to compound 10, compound 12 showed a different
binding mode in the colchicine-binding site with sulfonamide
moiety and benzoyl amide moiety switched. The benzyl group in
the sulfonamide moiety can extend into a small hydrophobic
pocket defined by Tyr 202, Ile 378, Leu 242, and Leu 255. A
hydrogen bond may be formed between the carbonyl group of
benzoyl amide moiety and the side chain of Asn 258. The 2,5-
dimethoxybenzyl moiety in compound 12 slightly shifted away
from the side chain of Ser 178, and the possible hydrogen bond
between them was forfeited. However, a hydrophobic interaction
may form between 2,5-dimethoxybenzyl moiety and Lys 352. The
estimated free energies for compound 10 and 12 for binding at the
colchicine site were determined to be 7.57 and 7.86 kcal/mol,
respectively. Their similar binding energy in the colchicine-binding
site may account for their similar inhibition to tubulin
polymerization.
2.4. Hsp27 targeting effect investigation
Previously, lead compound 5 inhibited both Hsp27 and tubulin
[22]. The newly synthesized derivatives 10 and 12 inhibited tubulin
and showed potent anti-proliferative activity. Whether they also
target Hsp27 is still unknown. In order to further elucidate their
anti-cancer mechanism, the capabilities of both compounds to
modulate the in vitro chaperone function of Hsp27 were evaluated.
By monitoring dithiothreitol (DTT)-induced insulin aggregation in
the presence of Hsp27, with or without the compounds, their
Hsp27 inhibition can be examined. In this in vitro chaperone ac-
tivity assays, Hsp27 exhibited potent inhibition of DTT-induced
insulin aggregation. Previous study showed that the correspond-
ing N-methylmethanesulfonamide 5 at 10 mM inhibited Hsp27
functions by 27% [22]. However, both compounds 10 and 12 did not
show inhibitory activity against Hsp27 chaperone activity at 10 mM,
suggesting Hsp27 targeting effect decreased in the new com-
pounds. Substitution of the methanesulfonamide at the C moiety of
compound 5 with ethanesulfonamide or benzylsulfonamide is
detrimental for its Hsp27 targeting effect. However, this modifica-
tion did not affect tubulin targeting effects. The results suggest that
smaller sulfonamide moiety is preferred for Hsp27 inhibition.
3. Conclusion
We synthesized various sulfonamide derivatives and acetamide
derivatives based on the previously reported compounds 2e5 [22].
The 2,5-dimethoxybenzyl group, which had been demonstrated to
be important for the anti-proliferative activity of these compounds,
was maintained for all the new compounds. The meth-
anesulfonamide group at the C moiety was changed to an acet-
amide group or a diversity of alkyl/aryl sulfonamide groups. The
SAR study revealed that most ethyl-, propyl-, phenyl-, benzyl-
sulfonamides showed weaker cell growth inhibition, compared to
the corresponding methanesulfonamides. Only N-methyl-
ethanesulfonamide 10 and N-methylbenzylsulfonamide 12 main-
tained similar potency. Further mechanism investigation indicated
that compounds 10 and 12 are potent inhibitors of tubulin poly-
merization. Their tubulin inhibitory activities are comparable to the
Fig. 2. Tubulin polymerization in the presence of different concentrations of compounds 10 and 12.
Fig. 3. Hsp27 chaperone activity for the protection of DTT induced insulin aggregation in the presence of different concentrations of compounds 10 and 12. The kinetic of the DTT
reduction-induced insulin aggregation was monitored in the absence of Hsp27 or in the presence of Hsp27, with or without compounds.
corresponding lead compound N-methylmethanesulfonamide 5.
However, both compounds did not show Hsp27 inhibition. The
substitution of methanesulfonamide with ethanesulfonamide or
benzylsulfonamide significantly impaired the Hsp27 inhibitory ef-
fects. The molecular docking simulation suggested that compounds
10 and 12may adopt different binding modes to be accommodated
in the colchicine binding site of tubulin. Future study will focus on
discerning the structural fragments that are important for Hsp27
inhibition, and develop new anti-cancer agents with better potency
to target both tubulin and Hsp27.
4. Experimental section
4.1. Chemistry
Chemicals were commercially available and used as received
without further purification. Moisture sensitive reactions were
carried out under a dry argon atmosphere in flame-dried glassware.
Thin-layer chromatography was performed on silica gel TLC plates
with fluorescence indicator 254 nm (Fluka). Flash column chro-
matography was performed using silica gel 60A (BDH, 40e63 mM).
Mass spectra were obtained on the ABI QStar Electrospray mass
spectrometer at Cleveland State University MS facility Center. All
the NMR spectra were recorded on a Bruker 400 MHz (13C NMR at
100MHz) using DMSO-d6 as solvent. Chemical shifts (d) for 1H NMR
spectra were reported in parts per million to residual solvent pro-
tons. The IR spectra were obtained on a Bruker ALPHA FT-IR spec-
trometer with ATR module.
All the compounds were prepared according to the previously
published procedures [22].
4.1.1. N-[3-(2,5-dimethoxy-benzyloxy)-4-(ethanesulfonyl-methyl-
amino)-phenyl]-4-methoxybenzamide (6)
1H NMR d 10.200 (1H, s), 7.972 (2H, d, J ¼ 8.8 Hz), 7.732 (1H, d,
J ¼ 2.4 Hz), 7.415 (1H, dd, J ¼ 2.4, 8.4 Hz), 7.250 (1H, d, J ¼ 8.8 Hz),
7.156 (1H, d, J ¼ 2.8 Hz), 7.081 (2H, d, J ¼ 9.2 Hz), 7.001 (1H, d,
J¼ 9.2 Hz), 6.905 (1H, dd, J¼ 2.8, 8.8 Hz), 5.083 (2H, s), 3.848 (3H, s),
3.785 (3H, s), 3.717 (3H, s), 3.136 (3H, s), 3.056 (2H, q, J ¼ 7.6 Hz),
1.114 (3H, t, J ¼ 7.6 Hz); 13C NMR d 165.43, 162.52, 155.62, 153.57,
151.37, 140.94, 131.79, 130.10, 127.20, 125.53, 124.70, 115.45, 114.39,
114.12, 112.68, 112.28, 105.58, 65.45, 56.27, 55.93, 55.88, 46.09,
38.36, 8.34; ESI-MS calculated for C26H31N2O7S [MþH]þ 515.19,
found: 514.98.
4.1.2. N-[3-(2,5-dimethoxy-benzyloxy)-4-(propanesulfonyl-methyl-
amino)-phenyl]-4-methoxybenzamide (7)
1H NMR d 10.200 (1H, s), 7.972 (2H, d, J ¼ 9.2 Hz), 7.732 (1H, d,
J¼ 2 Hz), 7.416 (1H, dd, J¼ 2, 8.4 Hz), 7.246 (1H, d, J ¼ 8.4 Hz), 7.148
(1H, d, J¼ 3.2 Hz), 7.081 (2H, d, J ¼ 9.2 Hz), 7.006 (1H, d, J¼ 9.2 Hz),
6.908 (1H, dd, J ¼ 3.2, 9.2 Hz), 5.080 (2H, s), 3.847 (3H,s), 3.787 (3H,
s), 3.715 (3H, s), 3.134 (3H, s), 2.984 (2H, m), 1.624 (2H, m), 0.812
(3H,t, J ¼ 7.2 Hz); 13C NMR d 165.43, 162.52, 155.61, 153.59, 151.37,
140.91, 131.79, 130.10, 127.20, 125.55, 124.77, 115.51, 114.31, 114.12,
112.69, 112.36,105.63, 65.45, 56.32, 55.93, 55.87, 53.09, 38.15, 17.21,
13.13; ESI-MS calculated for C27H33N2O7S [MþH]þ 529.20, found:
529.01.
4.1.3. N-[3-(2,5-dimethoxy-benzyloxy)-4-(benzylsulfonyl-methyl-
amino)-phenyl]-4-methoxybenzamide (8)
1H NMR d 10.191 (1H, s), 7.971 (2H, d, J ¼ 8.8 Hz), 7.722 (1H, d,
J ¼ 2.4 Hz), 7.354 (6H, m), 7.204 (1H, d, J ¼ 2.8 Hz), 7.081 (2H, d,
J ¼ 9.2 Hz), 6.991 (1H, d, J ¼ 8.8 Hz), 6.961 (1H, d, J ¼ 9.2 Hz), 6.867
(1H, dd, J ¼ 2.8, 8.8 Hz), 5.115 (2H, s), 4.415 (2H, s), 3.848 (3H, s),
3.741 (3H, s), 3.680 (3H, s), 3.074 (3H, s); 13C NMR d 165.43, 162.53,
155.70, 153.64, 151.21, 140.89, 131.40, 131.34, 130.38, 130.10, 128.74,
128.53, 127.20, 125.61, 125.03, 115.08, 114.43, 114.12, 112.63, 112.28,
105.59, 65.45, 57.21, 56.29, 55.93, 55.84, 38.46; ESI-MS calculated
for C31H33N2O7S [MþH]þ 577.20, found 576.98.
4.1.4. N-[3-(2,5-dimethoxy-benzyloxy)-4-(phenylsulfonyl-methyl-
amino)-phenyl]-4-methoxybenzamide (9)
1H NMR d 10.192 (1H, s), 7.958 (2H, d, J ¼ 8.8 Hz), 7.624 (3H, m),
7.539 (1H, m), 7.441 (3H, m), 7.074 (3H, m), 6.946 (1H, d, J¼ 8.8 Hz),
6.834 (2H, m), 4.802 (2H, s), 3.845 (3H, s), 3.769 (3H, s), 3.714 (3H,
s), 3.146 (3H, s); 13C NMR d 165.46, 162.52, 155.65, 153.54, 150.67,
141.07, 139.40, 133.01, 131.05, 130.09, 129.33, 127.45, 127.20, 125.61,
124.38, 114.31, 114.11, 113.67, 112.51, 112.01, 105.66, 65.00, 56.21,
55.92, 55.84, 38.24; ESI-MS calculated for C30H31N2O7S [MþH]þ
563.19, found: 562.96.
4.1.5. N-[3-(2,5-dimethoxy-benzyloxy)- 4-(ethanesulfonyl-methyl-
amino)-phenyl]-4-iodobenzamide (10)
IR n ¼ 1672 (C]O); 1H NMR d 10.398 (1H, s), 7.943 (2H, d,
J ¼ 8.4 Hz), 7.754 (2H, d, J ¼ 8.4 Hz), 7.703 (1H, d, J ¼ 2 Hz), 7.410
(1H, dd, J ¼ 2, 8.8 Hz), 7.267 (1H, d, J ¼ 8.8 Hz), 7.148 (1H, d,
J ¼ 3.2 Hz), 6.998 (1H, d, J ¼ 9.2 Hz), 6.904 (1H, dd, J ¼ 3.2, 8.8 Hz),
5.083 (2H, s), 3.781 (3H, s), 3.714 (3H, s), 3.135 (3H, s), 3.059 (2H, q,
J¼ 7.2 Hz), 1.114 (3H, t, J¼ 7.2 Hz); 13C NMR d 165.63,155.64, 153.49,
151.40, 140.32, 137.83, 134.48, 131.82, 130.03, 125.39, 125.20, 115.50,
Fig. 4. The molecular docking simulation of the interaction of tubulin with compounds
10 and 12. Proposed binding mode of compound 10 (A) and 12 (B) at the colchicine
binding site .The tubulin polypeptide backbones are shown as ribbons. Only important
active site amino acids around compounds are shown for clarity.
114.46, 112.96, 112.34, 105.83, 99.80, 65.49, 56.27, 55.86, 46.15,
38.30, 8.26; ESI-MS calculated for C25H28IN2O6S [MþH]þ 611.07,
found: 610.88.
4.1.6. N-[3-(2,5-dimethoxy-benzyloxy)- 4-(propanesulfonyl-
methyl-amino)-phenyl]-4-iodobenzamide (11)
1H NMR d 10.399 (1H, s), 7.944 (2H, d, J ¼ 8.8 Hz), 7.756 (2H, d,
J ¼ 8.8 Hz), 7.704 (1H, d, J ¼ 2.4 Hz), 7.412 (1H, dd, J ¼ 2, 8.4 Hz),
7.264 (1H, d, J ¼ 8.8 Hz), 7.140 (1H, d, 3.2 Hz), 7.004 (1H, d,
J¼ 8.8 Hz), 6.907 (1H, dd, J¼ 2.8, 8.8 Hz), 5.080 (2H, s), 3.784 (3H, s),
3.712 (3H, s), 3.133 (3H, s), 2.985 (2H, m),1.623 (2H, m), 0.812 (3H, t,
J ¼ 7.6 Hz); 13C NMR d 165.35, 155.64, 153.59, 151.36, 140.47, 137.78,
134.54, 131.86, 130.07, 125.50, 125.18, 115.50, 114.33, 112.84, 112.38,
105.78, 99.94, 65.49, 56.33, 55.88, 53.11, 38.14, 17.21, 13.13; ESI-MS
calculated for C26H30IN2O6S [MþH]þ 625.09, found 624.87.
4.1.7. N-[3-(2,5-dimethoxy-benzyloxy)-4-(benzylsulfonyl-methyl-
amino)-phenyl]-4-iodobenzamide (12)
IR n ¼ 1645 (C]O); 1H NMR d 10.391 (1H, s), 7.944 (2H, d,
J ¼ 8.4 Hz), 7.754 (2H, d, J ¼ 8.4 Hz), 7.692 (1H, d, J ¼ 2.4 Hz), 7.353
(6H, m), 7.196 (1H, d, J¼ 3.2 Hz), 7.006 (1H, d, J¼ 8.4 Hz), 6.959 (1H,
d, J ¼ 9.2 Hz), 6.866 (1H, dd, J ¼ 2.8, 8.8 Hz), 5.114 (2H, s), 4.418 (2H,
s), 3.738 (3H, s), 3.677 (3H, s), 3.072 (3H, s); 13C NMR d 165.35,
155.72, 153.64, 151.20, 140.45, 137.79, 134.54, 131.40, 130.36, 130.07,
128.74, 128.54, 125.56, 125.43, 115.05, 114.43, 112.77, 112.29, 105.73,
99.95, 65.48, 57.22, 56.30, 55.84, 38.45; ESI-MS calculated for
C30H30IN2O6S [MþH]þ 673.09, found 672.84.
4.1.8. N-[3-(2,5-dimethoxy-benzyloxy)-4-(phenylsulfonyl-methyl-
amino)-phenyl]-4-iodobenzamide (13)
1H NMR d 10.390 (1H, s), 7.937 (2H, d, J ¼ 8.4 Hz), 7.741 (2H, d,
J ¼ 8.4 Hz), 7.619 (3H, m), 7.541 (1H, m), 7.431 (3H, m), 7.094 (1H, d,
J ¼ 8.8 Hz), 6.945 (1H, d, J ¼ 8.8 Hz), 6.833 (2H, m), 4.801 (2H, s),
3.765 (3H, s), 3.712 (3H, s), 3.146 (3H, s); 13C NMR d 165.38, 155.67,
153.53, 150.66, 140.64, 139.36, 137.77, 134.54, 133.04, 131.15, 130.07,
129.35, 127.45, 125.56, 124.77, 114.31, 113.69, 112.64, 112.03, 105.79,
99.95, 65.05, 56.22, 55.85, 38.22; ESI-MS calculated for
C29H28IN2O6S [MþH]þ 659.07, found: 658.86.
4.1.9. N-[3-(2,5-dimethoxy-benzyloxy)-4-(ethanesulfonyl-methyl-
amino)-phenyl]-3,4-dimethoxybenzamide (14)
1H NMR d 10.191 (1H, s), 7.736 (1H, d, J ¼ 2.4 Hz), 7.643 (1H, dd,
J ¼ 2.4, 8.4 Hz), 7.534 (1H, d, J ¼ 2 Hz), 7.398 (1H, dd, J ¼ 2, 8.4 Hz),
7.259 (1H, d, J ¼ 8.4 Hz), 7.159 (1H, d, J ¼ 3.2 Hz), 7.104 (1H, d,
J ¼ 8.4 Hz), 7.002 (1H, d, J ¼ 9.2 Hz), 6.907 (1H, dd, J ¼ 2.8, 8.8 Hz),
5.086 (2H, s), 3.852 (3H, s), 3.847 (3H, s), 3.785 (3H, s), 3.719 (3H, s),
3.138 (3H, s), 3.059 (2H, q, J ¼ 7.6 Hz), 1.115 (3H, t, J ¼ 7.6 Hz); 13C
NMR d 165.47, 155.63, 153.58, 152.32, 151.38, 148.87, 140.88, 131.79,
127.24, 125.53, 124.77, 121.54, 115.47, 114.41, 112.80, 112.29, 111.69,
111.42, 105.69, 65.47, 56.19, 56.16, 55.88, 46.10, 38.36, 8.34; ESI-MS
calculated for C27H33N2O8S [MþH]þ 545.20, found: 544.98.
4.1.10. N-[3-(2,5-dimethoxy-benzyloxy)-4-(propanesulfonyl-
methyl-amino)-phenyl]-3,4-dimethoxybenzamide (15)
1H NMR d 10.192 (1H, s), 7.735 (1H, d, J ¼ 2 Hz), 7.644 (1H, dd,
J ¼ 2, 8.4 Hz), 7.534 (1H, d, J ¼ 2 Hz), 7.398 (1H, dd, J ¼ 2, 8.4 Hz),
7.256 (1H, d, J ¼ 8.8 Hz), 7.150 (1H, d, J ¼ 2.8 Hz), 7.104 (1H, d,
J¼ 8.4 Hz), 7.007 (1H, d, 8.8 Hz), 6.910 (1H, dd, J¼ 3.2, 8.8 Hz), 5.083
(1H, s), 3.582 (3H, s), 3.847 (3H, s), 3.787 (3H, s), 3.717 (3H, s), 3.136
(3H, s), 2.979 (2H, m), 1.623 (2H, m), 0.811 (3H, t, J ¼ 7.2 Hz); 13C
NMR d 165.46, 155.62, 153.60, 152.31, 151.37, 148.87, 140.85, 131.77,
127.23, 125.54, 124.88, 121.53, 115.53, 114.34, 112.80, 112.39, 111.69,
111.41, 105.73, 65.47, 56.33, 56.20, 56.10, 55.88, 53.10, 38.15, 17.21,
13.13; ESI-MS calculated for C28H35N2O8S [MþH]þ 559.20, found:
559.02.
4.1.11. N-[3-(2,5-dimethoxy-benzyloxy)- 4-(ethanesulfonyl-methyl-
amino)-phenyl]-4-bromobenzamide (16)
1H NMR d 10.422 (1H, s), 7.921 (2H, d, J ¼ 8.8 Hz), 7.773 (2H, d,
J ¼ 8.8 Hz), 7.706 (1H, d, J ¼ 2 Hz), 7.412 (1H, dd, J ¼ 2.4, 8.8 Hz),
7.272 (1H, d, J ¼ 8.8 Hz), 7.149 (1H, d, J ¼ 3.2 Hz), 7.000 (1H, d,
J¼ 9.2 Hz), 6.905 (1H, dd, J¼ 3.2, 9.2 Hz), 5.086 (2H, s), 3.782 (3H, s),
3.714 (3H, s), 3.137 (3H, s), 3.062 (2H, q, J ¼ 7.6 Hz), 1.116 (3H, t,
J ¼ 7.6 Hz); 13C NMR d 165.09, 155.65, 153.58, 151.37, 140.49, 134.24,
131.92, 130.27, 126.00, 125.49, 125.14, 115.43, 114.40, 112.83, 112.29,
105.74, 65.49, 56.28, 55.88, 46.11, 38.34, 8.34; ESI-MS calculated for
C25H28BrN2O6S [MþH]þ 563.09, found: 562.90.
4.1.12. N-[3-(2,5-dimethoxy-benzyloxy)- 4-(propanesulfonyl-
methyl-amino)-phenyl]-4-bromobenzamide (17)
1H NMR d 10.421 (1H, s), 7.923 (2H, d, J ¼ 8.8 Hz), 7.773 (2H, d,
J ¼ 8.8 Hz), 7.708 (1H, d, J ¼ 1.6 Hz), 7.414 (1H, dd, J ¼ 2, 8.8 Hz),
7.270 (1H, d, J ¼ 8.4 Hz), 7.142 (1H, d, J ¼ 3.2 Hz), 7.005 (1H, d,
J¼ 8.8 Hz), 6.908 (1H, dd, J¼ 2.8, 8.8 Hz), 5.084 (2H, s), 3.785 (3H, s),
3.714 (3H, s), 3.136 (3H, s), 2.987 (2H, m),1.626 (2H, m), 0.814 (3H, t,
J ¼ 7.2 Hz); 13C NMR d 165.09, 155.64, 153.59, 151.36, 140.46, 134.24,
131.92, 130.27, 126.00, 125.50, 125.21, 115.50, 114.33, 112.85, 112.38,
105.79, 65.49, 56.33, 55.87, 53.11, 38.13, 17.21, 13.13; ESI-MS calcu-
lated for C26H30BrN2O6S [MþH]þ 577.10, found 576.92.
4.1.13. N-[3-(2,5-dimethoxy-benzyloxy)-4-(ethanesulfonyl-amino)-
phenyl]-4-methoxybenzamide (18)
1H NMR d 10.136 (1H, s), 8.916 (1H, s), 7.959 (2H, d, J ¼ 8.8 Hz),
7.680 (1H, d, J ¼ 2 Hz), 7.384 (1H, dd, J ¼ 2, 8.4 Hz), 7.256 (1H, d,
J ¼ 3.2 Hz), 7.215 (1H, d, J ¼ 8.4 Hz), 7.069 (2H, d, J ¼ 8.8 Hz), 6.984
(1H, d, J¼ 8.8 Hz), 6.887 (1H, dd, J¼ 3.2, 8.8 Hz), 5.061 (2H, s), 3.842
(3H, s), 3.792 (3H, s), 3.724 (3H, s), 2.956 (2H, q, J ¼ 7.2 Hz), 1.128
(3H, t, J ¼ 7.2 Hz); 13C NMR d 165.31, 162.44, 153.65, 152.90, 151.16,
139.10, 130.04, 128.08, 127.30, 125.72, 121.26, 115.58, 114.09, 113.96,
112.84, 112.09, 105.63, 65.49, 56.29, 55.93, 55.91, 46.75, 8.46; ESI-
MS calculated for C25H29N2O7S [MþH]þ: 501.17, found: 500.96.
4.1.14. N-[3-(2,5-dimethoxy-benzyloxy)-4-(propanesulfonyl-
amino)-phenyl]-4-methoxybenzamide (19)
1H NMR d10.137 (1H, s), 8.941 (1H, s), 7.960 (2H, d, J ¼ 9.2 Hz),
7.678 (1H, d, J ¼ 2 Hz), 7.390 (1H, dd, J ¼ 2, 8.8 Hz), 7.270 (1H, d,
J ¼ 3.2 Hz), 7.213 (1H, d, J ¼ 8.8 Hz), 7.070 (2H, d, J ¼ 9.2 Hz), 6.986
91H, d, J¼ 9.2 Hz), 6.886 (1H, dd, J¼ 3.2, 9.2 Hz), 5.068 (2H, s), 3.843
(3H, s), 3.797 (3H, s), 3.728 (3H, s), 2.918 (2H, m), 1.654 (2H, m),
0.790 (3H, t, J ¼ 7.2 Hz); 13C NMR d 165.31, 162.44, 153.70, 152.82,
151.07, 139.04, 130.04, 127.96, 127.30, 125.80, 121.34, 115.47, 114.09,
113.82, 112.88, 112.17, 105.70, 65.42, 56.37, 55.95, 55.92, 54.12, 17.33,
13.01; ESI-MS calculated for C26H31N2O7S [MþH]þ 515.19, found:
514.99.
4.1.15. N-[3-(2,5-dimethoxy-benzyloxy)-4-(benzylsulfonyl-amino)-
phenyl]-4-methoxybenzamide (20)
1H NMR d 10.149 (1H, s), 8.993 (1H, s), 7.970 (2H, d, J ¼ 8.8 Hz),
7.709 (1H, d, J ¼ 2 Hz), 7.384 (1H, dd, J ¼ 2, 8.4 Hz), 7.304 (6H, m),
7.150 (1H, d, J ¼ 8.8 Hz), 7.075 (2H, d, J ¼ 8.8 Hz), 6.949 (1H, d,
J¼ 9.2 Hz), 6.865 (1H, dd, J¼ 2.8, 8.8 Hz), 5.103 (2H, s), 4.309 (2H, s),
3.846 (3H, s), 3.740 (3H, s), 3.697 (3H, s); 13C NMR d 165.32, 162.45,
153.67, 152.79, 151.16, 139.01, 131.29, 130.33, 130.05, 128.69, 128.46,
127.62, 127.31, 125.73, 121.38, 115.54, 114.10, 112.83, 112.14, 105.69,
65.55, 58.68, 56.29, 55.92; ESI-MS calculated for C30H31N2O7S
[MþH]þ 563.19, found: 562.97.
4.1.16. N-[3-(2,5-dimethoxy-benzyloxy)-4-(phenylsulfonyl-amino)-
phenyl]-4-methoxybenzamide (21)
1H NMR d 10.082 (1H, s), 9.551 (1H, s), 7.925 (2H, d, J ¼ 8.8 Hz),
7.611 (2H, m), 7.473 (2H, m), 7.345 (3H, m), 7.155 (1H, d, J ¼ 8.4 Hz),
7.099 (1H, d, J ¼ 3.2 Hz), 7.051 (2H, d, J ¼ 9.2 Hz), 6.943 (1H, d,
J¼ 8.8 Hz), 6.853 (1H, dd, J¼ 3.2, 8.8 Hz), 4.692 (2H, s), 3.833 (3H, s),
3.775 (3H, s), 3.758 (3H, s); 13C NMR d 165.30, 162.43, 153.72,
152.75, 150.48, 140.95, 139.15, 132.73, 130.02, 129.08, 127.41, 127.27,
127.00, 125.96, 120.82, 114.83, 114.07, 113.12, 112.78, 111.76, 105.65,
65.14, 56.25, 56.00, 55.89; ESI-MS calculated for C29H29N2O7S
[MþH]þ 549.17, found: 548.95.
4.1.17. N-[3-(2,5-dimethoxy-benzyloxy)-4-(ethanesulfonyl-amino)-
phenyl]-4-iodobenzamide (22)
1H NMR d 10.336 (1H, s), 8.944 (1H, s), 7.931 (2H, d, J ¼ 8.8 Hz),
7.744 (2H, d, J¼ 8.4 Hz), 7.657 (1H, d, J¼ 2.4 Hz), 7.383 (1H, dd, J¼ 2,
8.4 Hz), 7.245 (2H, m), 6.982 (1H, d, J ¼ 8.8 Hz), 6.886 (1H, dd,
J ¼ 3.2, 9.2 Hz), 5.063 (2H, s), 3.789 (3H, s), 3.721 (3H, s), 2.962 (2H,
q, J ¼ 7.2 Hz), 1.131 (3H, t, J ¼ 7.2 Hz); 13C NMR d 165.22, 153.64,
152.85, 151.15, 138.62, 137.75, 134.63, 130.05, 128.02, 125.67, 121.69,
115.56, 113.96, 112.97, 112.10, 105.74, 99.81, 65.52, 56.30, 55.93,
46.78, 8.46; ESI-MS calculated for C24H26IN2O6S [MþH]þ: 597.06,
found: 596.85.
4.1.18. N-[3-(2,5-dimethoxy-benzyloxy)-4-(propanesulfonyl-
amino)-phenyl]-4-iodobenzamide (23)
1H NMR d 10.335 (1H, s), 8.972 (1H, s), 7.931 (2H, d, J ¼ 8.8 Hz),
7.745 (2H, d, J¼ 8.8 Hz), 7.655 (1H, d, J¼ 2.4 Hz), 7.389 (1H, dd, J¼ 2,
8.4 Hz), 7.262 (1H, d, J¼ 3.2 Hz), 7.231 (1H, d, J¼ 8.4 Hz), 6.984 (1H,
d, J¼ 9.2 Hz), 6.885 (1H, dd, J¼ 3.2, 9.2 Hz), 5.070 (2H, s), 3.793 (3H,
s), 3.725 (3H, s), 2.924 (2H, m), 1.655 (2H, m), 0.792 (3H, t,
J ¼ 7.6 Hz); 13C NMR d 165.22, 153.69, 152.77, 151.06, 138.57, 137.75,
134.63, 130.05, 127.89, 125.74, 121.77, 115.45, 113.83, 113.00, 112.16,
105.80, 99.81, 65.46, 56.36, 55.95, 54.14, 17.33, 13.01; ESI-MS
calculated for C25H28IN2O6S [MþH]þ 611.07, found 610.88.
4.1.19. N-[3-(2,5-dimethoxy-benzyloxy)-4-(benzylsulfonyl-amino)-
phenyl]-4-iodobenzamide (24)
1H NMR d 10.349 (1H, s), 9.018 (1H, s), 7.937 (2H, d, J ¼ 8.4 Hz),
7.755 (2H, d, J ¼ 8.4 Hz), 7.684 (1H, d, J ¼ 2 Hz), 7.382 (1H, dd, J ¼ 2,
8.4 Hz), 7.304 (6H, m), 7.164 (1H, d, J ¼ 8.4 Hz), 6.948 (1H, d,
J¼ 9.2 Hz), 6.864 (1H, dd, J¼ 2.8, 9.2 Hz), 5.104 (2H, s), 4.317 (2H, s),
3.738 (3H, s), 3.694 (3H, s); 13C NMR d 165.22, 153.67, 152.71, 151.16,
138.51, 137.76, 134.65, 131.29, 130.30, 130.05, 128.70, 128.47, 127.50,
125.68, 121.82, 115.53, 114.07, 112.96, 112.14, 105.81, 99.82, 65.59,
58.70, 56.30, 55.91; ESI-MS calculated for C29H28IN2O6S [MþH]þ
659.07, found: 658.84.
4.1.20. N-[3-(2,5-dimethoxy-benzyloxy)-4-(phenylsulfonyl-amino)-
phenyl]-4-iodobenzamide (25)
1H NMR d 10.278 (1H, s), 9.579 (1H, s), 7.911 (2H, d, J ¼ 8.4 Hz),
7.709 (2H, d, J ¼ 8.8 Hz), 7.614 (2H, m), 7.464 (2H, m), 7.339 (3H, m),
7.173 (1H, d, J ¼ 8.8 Hz), 7.086 (1H, d, J ¼ 3.2 Hz), 6.941 (1H, d,
J¼ 9.2 Hz), 6.852 (1H, dd, J¼ 3.2, 9.2 Hz), 4.696 (2H, s), 3.770 (3H, s),
3.753 (3H, s); 13C NMR d 165.20, 153.71, 152.70, 150.48, 140.92,
138.68, 137.72, 134.61, 132.76, 130.02, 129.11, 127.35, 127.00, 125.90,
121.23, 114.82, 113.14, 112.89, 111.78, 105.75, 99.80, 65.17, 56.27,
56.00; ESI-MS calculated for C28H26IN2O6S [MþH]þ 645.06, found
644.83.
4.1.21. N-[3-(2,5-dimethoxy-benzyloxy)- 4-(ethanesulfonyl-
amino)-phenyl]-3,4-dimethoxybenzamide (26)
1H NMR d 10.129 (1H, s), 8.922 (1H, s), 7.682 (1H, d, J ¼ 2.4 Hz),
7.628 (1H, dd, J¼ 2.4, 8.4 Hz), 7.528 (1H, d, J¼ 2.4 Hz), 7.366 (1H, dd,
J¼ 2, 8.4 Hz), 7.260 (1H, d, J¼ 2.8 Hz), 7.227 (1H, d, J¼ 8.8 Hz), 7.092
(1H, d, J ¼ 8.4 Hz), 6.985 (1H, d, J ¼ 9.2 Hz), 6.889 (1H, dd, J ¼ 3.2,
8.8 Hz), 5.065 (2H, s), 3.847 (3H, s), 3.842 (3H, s), 3.792 (3H, s), 3.727
(3H, s), 2.962 (2H, q, J ¼ 7.2 Hz), 1.131 (3H, t, J ¼ 7.2 Hz); 13C NMR
d 165.36, 153.64, 152.91, 152.22, 151.16, 148.83, 139.03, 128.08,
127.33, 125.70, 121.48, 121.32, 115.61, 113.95, 112.99, 112.08, 111.63,
111.39, 105.73, 65.49, 56.28, 56.17, 56.15, 55.92, 46.76, 8.46; ESI-MS
calculated for C26H31N2O8S [MþH]þ: 531.18, found: 530.97.
4.1.22. N-[3-(2,5-dimethoxy-benzyloxy)-4-(propanesulfonyl-
amino)-phenyl]-3,4-dimethoxybenzamide (27)
1H NMR d 10.128 (1H, s), 8.950 (1H, s), 7.678 (1H, d, J ¼ 2.4 Hz),
7.627 (1H, dd, J ¼ 2, 8.4 Hz), 7.526 (1H, d, J ¼ 2 Hz), 7.370 (1H, dd,
J¼ 2, 8.8 Hz), 7.273 (1H, d, J¼ 2.8 Hz), 7.223 (1H, d, J¼ 8.8 Hz), 7.092
(1H, d, J ¼ 8.8 Hz), 6.987 (1H. d, J ¼ 9.2 Hz), 6.888 (1H, d, J ¼ 2.8,
9.2 Hz), 5.071 (2H, s), 3.847 (3H, s), 3.842 (3H, s), 3.797 (3H, s), 3.730
(3H, s), 2.922 (2H, m), 1.654 (2H, m), 0.790 (3H, t, J ¼ 7.2 Hz); 13C
NMR d 165.35, 153.70, 152.82, 152.22, 151.07, 148.83, 138.97, 127.94,
127.33, 125.78, 121.47, 121.41, 115.50, 113.82, 113.02, 112.15, 111.63,
111.40, 105.81, 65.44, 56.35, 56.17, 56.15, 55.94, 54.13, 17.34, 13.00;
ESI-MS calculated for C27H33N2O8S [MþH]þ 545.20, found: 544.98.
4.1.23. N-[3-(2,5-dimethoxy-benzyloxy)-4-(ethanesulfonyl-
amino)-phenyl]-4-bromobenzamide (28)
1H NMR d 10.358 (1H, s), 8.947 (1H, s), 7.909 (2H, d, J ¼ 8.8 Hz),
7.760 (2H, d, J ¼ 8.8 Hz), 7.658 (1H, d, J ¼ 2 Hz), 7.384 (1H, dd, J ¼ 2,
8.4 Hz), 7.248 (2H, m), 6.983 (1H, d, J ¼ 8.8 Hz), 6.886 (1H, dd,
J ¼ 2.8, 8.8 Hz), 5.065 (2H, s), 3.789 (3H, s), 3.721 (3H, s), 2.963 (2H,
q, J ¼ 7.2 Hz), 1.131 (3H, t, J ¼ 7.2); 13C NMR d 164.95, 153.64, 152.85,
151.15, 138.61, 134.33, 131.88, 130.24, 128.05, 125.89, 125.66, 121.71,
115.55, 113.94, 112.97, 112.08, 105.74, 65.51, 56.28, 55.92, 46.78,
8.47; ESI-MS calculated for C24H26BrN2O6S [MþH]þ: 549.07, found:
548.86.
4.1.24. N-[3-(2,5-dimethoxy-benzyloxy)-4-(propanesulfonyl-
amino)-phenyl]-4-bromobenzamide (29)
1H NMR d 10.356 (1H, s), 8.973 (1H, s), 7.909 (2H, d, J ¼ 8.8 Hz),
7.760 (2H, d, J¼ 8.8 Hz), 7.652 (1H, s), 7.388 (1H, d, J¼ 8.4 Hz), 7.262
(1H, d, J¼ 3.2 Hz), 7.234 (1H, d, J ¼ 8.4 Hz), 6.985 (1H, d, J¼ 8.8 Hz),
6.885 (1H, dd, J¼ 2.8, 8.8 Hz), 5.071 (2H, s), 3.794 (3H, s), 3.725 (3H,
s), 2.924 (2H, m), 1.655 (2H, m), 0.793 (3H, t, J ¼ 7.6 Hz); 13C NMR
d 164.95, 153.69, 152.78, 151.04, 138.58, 134.33, 131.88, 130.24,
127.95, 125.90, 125.73, 121.78, 115.45, 113.77, 112.99, 112.11, 105.78,
65.44, 56.33, 55.93, 54.13, 17.35, 13.01; ESI-MS calculated for
C25H28BrN2O6S [MþH]þ 563.09, found: 562.91.
4.1.25. N-[3-(2,5-dimethoxy-benzyloxy)-4-acetamido-phenyl]-4-
methoxybenzamide (30)
1H NMR d 10.063 (1H, s), 9.171 (1H, s), 7.950 (2H, d, J ¼ 8.8 Hz),
7.677 (1H, d, J¼ 8.4 Hz), 7.623 (1H, s), 7.355 (1H, d, J¼ 8.8 Hz), 7.141
(1H, d, J¼ 2.8 Hz), 7.058 (2H, d, J ¼ 8.8 Hz), 6.981 (1H, d, J¼ 9.2 Hz),
6.859 (1H, dd, J¼ 2.8, 8.8 Hz), 5.097 (2H, s), 3.838 (3H, s), 3.805 (3H,
s), 3.718 (3H, s), 2.070 (3H, s); 13C NMR d 168.63, 165.15, 162.36,
153.68, 150.90, 149.91, 136.92, 129.98, 127.40, 126.16, 123.99, 123.61,
114.50, 114.05, 113.66, 112.74, 112.24, 105.88, 65.44, 56.39, 55.90,
55.82, 24.06; ESI-MS calculated for C25H27N2O6 [MþH]þ 451.19,
found: 450.99.
4.1.26. N-[3-(2,5-dimethoxy-benzyloxy)-4-acetamido-phenyl]-3,4-
dimethoxybenzamide (31)
1H NMR d 10.056 (1H, s), 9.172 (1H, s), 7.690 (1H, d, J ¼ 8.8 Hz),
7.606 (2H, m), 7.522 (1H, d, J¼ 1.6 Hz), 7.327 (1H, d, J¼ 9.2 Hz), 7.142
(1H, d, J¼ 3.2 Hz), 7.080 (1H, d, J ¼ 8.4 Hz), 6.982 (1H, d, J¼ 8.8 Hz),
6.861 (1H, dd, J¼ 2.8, 8.8 Hz), 5.099 (2H, s), 3.842 (3H, s), 3.837 (3H,
s), 3.804 (3H, s), 3.720 (3H, s), 2.072 (3H, s); 13C NMR d 168.65,
165.21, 153.68, 152.13, 150.91, 149.90, 148.81, 136.85, 127.45, 126.16,
123.96, 123.70, 121.42, 114.55, 113.65, 112.92, 112.21, 111.61, 111.38,
106.03, 65.48, 56.36, 56.14, 55.80, 24.07; ESI-MS calculated for
C26H29N2O7 [MþH]þ 481.20, found 481.01.
4.1.27. N-[3-(2,5-dimethoxy-benzyloxy)-4-acetamido-phenyl]-4-
bromobenzamide (32)
1H NMR d 10.286 (1H, s), 9.192 (1H, s), 7.901 (2H, d, J ¼ 8.4 Hz),
7.748 (2H, d, J ¼ 8.4 Hz), 7.710 (1H, d, J ¼ 8.8 Hz), 7.600 (1H, d,
J ¼ 2 Hz), 7.357 (1H, d, J ¼ 8.4 Hz), 7.133 ( 1H, d, J ¼ 2.8 Hz), 6.981
(1H, d, J¼ 9.2 Hz), 6.860 (1H, dd, J¼ 3.2, 8.8 Hz), 5.102 (2H, s), 3.803
(3H, s), 3.715 (3H, s), 2.075 (3H, s); 13C NMR d 168.65, 164.77, 153.67,
150.91, 149.85, 136.45, 134.43, 131.84, 130.20, 126.10, 125.76, 123.95,
114.51, 113.67, 112.86, 112.25, 105.96, 99.99, 65.47, 56.39, 55.82,
24.08; ESI-MS calculated for C24H24BrN2O5 [MþH]þ 499.09, found:
498.89.
4.1.28. N-[3-(2,5-dimethoxy-benzyloxy)-4-acetamido-phenyl]-4-
iodobenzamide (33)
1H NMR d 10.263 (1H, s), 9.188 (1H, s), 7.918 (2H, d, J ¼ 8.8 Hz),
7.730 (3H, m), 7.599 (1H, d, J ¼ 2 Hz), 7.253 (1H, dd, J ¼ 2, 8.8 Hz),
7.131 (1H, d, J ¼ 3.2 Hz), 6.979 (1H, d, J ¼ 8.8 Hz), 6.858 (1H, dd,
J ¼ 3.2, 9.2 Hz), 5.099 (2H, s), 3.801 (3H, s), 3.714 (3H, s), 2.073 (3H,
s); 13C NMR d 168.66, 165.04, 153.67, 150.91, 149.86, 137.71, 136.45,
134.73, 130.02, 126.11, 123.99, 123.95, 114.51, 113.68, 112.86, 112.25,
105.95, 99.66, 65.47, 56.40, 55.82, 24.08; ESI-MS calculated for
C24H24IN2O5 [MþH]þ 547.07, found 546.86.
4.2. Biological studies
4.2.1. Cell culture
Four breast cancer cell lines including SKBR-3, MCF-7, MDA-MB-
231, and MDA-MB-468 were obtained from ATCC (Rockville, MD).
The cells were maintained in RPMI1640 medium supplemented
with 10% fetal bovine serum (FBS), 2 mmol/l L-Glutamine, 1 mmol/l
sodium pyruvate, 100 U/ml penicillinestreptomycin. FBS was heat
inactivated for 30min in a 56 Cwater bath before use. Cell cultures
were grown at 37 C, in a humidified atmosphere of 5% CO2 in a
VWR CO2 incubator (Bridgeport NJ).
4.2.2. Cell viability analysis
The effects of the new derivatives on the viability of four breast
cancer cell lines were assessed using the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl-2H-tetrazolium bromide assay in six replicates.
Cells were grown in RPMI1640 medium in 96-well, flat-bottomed
plates for 24 h, and were exposed to various concentrations of
the compounds dissolved in DMSO (final concentration 0.1%) in
media for 48 h. Controls received DMSO vehicle at a concentration
equal to that in drug-treated cells. The medium was removed,
replaced by 200 mL of 0.5 mg/ml of 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl-2H-tetrazolium bromide in fresh media, and cells
were incubated in the CO2 incubator at 37 C for 2 h. Supernatants
were removed from the wells, and the reduced 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide dye
was solubilized in 200 mL/well DMSO. Absorbance at 570 nm was
determined on a plate reader. Statistical and graphical information
was determined using GraphPad Prism software (GraphPad Soft-
ware Incorporated) and Microsoft Excel (Microsoft Corporation).
IC50 values were determined using nonlinear regression analysis.
4.2.3. Tubulin polymerization assay
100 mL microtubule-associated protein-rich tubulin (2 mg/ml,
bovine brain, Cytoskeleton) in buffer containing 80 mM PIPES (pH
6.9), 2 mM MgCl2, 0.5 mM EGTA, and 5% glycerol was mixed with
DMSO (as control) or various concentrations of 10 and 12 in DMSO
and incubated at 37 C. 1 mL of 100 mM GTP was added to the
mixture to initiate the tubulin polymerization. The absorbance was
monitored at 340 nm over 20 min using a Varian Cary 50 series
spectrophotometer.
4.2.4. Hsp27 chaperone activity assay
A mixture of 0.24 mg/ml human recombinant insulin (Life
Technologies), 0.02 mg/ml Hsp27 (Cell Sciences), and compounds
10 and 12 in 98 ml sodium phosphate buffer, pH 7.4, was incubated
at 37 C for 5 min, whereupon 2 mL of 1 M DTT in the same assay
buffer was added to initiate the insulin aggregation. The absor-
bancewas monitored at 400 nm over 30min using a Varian Cary 50
series spectrophotometer. A mixture of 0.24 mg/ml insulin in the
absence or presence of 0.02 mg/ml Hsp27 with DMSO was used as
control.
5. Molecular docking simulation
Molecular docking of compounds 10 and 12 into the crystal
structure of tubulin was performed using software AUTODOCK 4.
The X-ray crystal structures of tubulin with PDB code 1SA0 from
Protein Data Bank was used for docking simulation of compounds
into the colchicine binding site. To prepare tubulin for autodock, all
hydrogens were added and the ligand with identifier CN2700 in
1SA0 was deleted. Compound 10 and 12 were drawn and energy
minimized with MM2 force field using Chem3D Ultra 10.0 (Cam-
bridge Soft Corp., US). Autogrid was used to pre-calculate the grid
maps of the binding energy between tubulin and compounds. A
grid box size of 44 46 42 points in x, y and z directions was built
and the grid center was located in x ¼ 116.909, y ¼ 89.688,
z ¼ 7.094. For running autodock, Lamarckian genetic algorithmwas
chosen as the search method. Genetic algorithm parameters were
set as default. The top docked conformation for each compound
was retained for analysis.
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